AR025549A1 - Mofetil micofelonato en asociacion con peg-ifn-alfa - Google Patents
Mofetil micofelonato en asociacion con peg-ifn-alfaInfo
- Publication number
- AR025549A1 AR025549A1 ARP000104149A ARP000104149A AR025549A1 AR 025549 A1 AR025549 A1 AR 025549A1 AR P000104149 A ARP000104149 A AR P000104149A AR P000104149 A ARP000104149 A AR P000104149A AR 025549 A1 AR025549 A1 AR 025549A1
- Authority
- AR
- Argentina
- Prior art keywords
- ifn
- peg
- association
- micofelonate
- mofetil
- Prior art date
Links
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 title 1
- 229950007856 mofetil Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 abstract 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 abstract 1
- 229960000951 mycophenolic acid Drugs 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
El empleo de una cantidad terapéuticamente efectiva de INF-alfa o PEG-IFN-alfa en asociacion con una cantidad terapéuticamente efectiva de una salfarmacéuticamente aceptable o profármaco de ácido micofenolico para la preparacion de medicamentos paratratar pacientes con enfermedades hepáticas. Loscomponentes se administran durante un período de tiempo por lo menos suficiente para reducir la cantidad de HCV-RNA presente en la sangre periférica de dichopaciente a menos de 100 copias/ml a 24semana s después de terminar el tratamiento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99115950 | 1999-08-13 | ||
| US18790700P | 2000-03-08 | 2000-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR025549A1 true AR025549A1 (es) | 2002-12-04 |
Family
ID=26153083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000104149A AR025549A1 (es) | 1999-08-13 | 2000-08-11 | Mofetil micofelonato en asociacion con peg-ifn-alfa |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20010046957A1 (es) |
| KR (1) | KR20020020809A (es) |
| AR (1) | AR025549A1 (es) |
| CO (1) | CO5180574A1 (es) |
| HK (1) | HK1048951A1 (es) |
| HR (1) | HRP20020118A2 (es) |
| IL (1) | IL147612A0 (es) |
| MA (1) | MA26814A1 (es) |
| NO (1) | NO20020704D0 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7121402B2 (en) * | 2003-04-09 | 2006-10-17 | Reactive Nano Technologies, Inc | Container hermetically sealed with crushable material and reactive multilayer material |
| US20050142495A1 (en) * | 2003-10-09 | 2005-06-30 | David Peter Van Heerden | Methods of controlling multilayer foil ignition |
| US7441688B2 (en) | 2003-11-04 | 2008-10-28 | Reactive Nanotechnologies | Methods and device for controlling pressure in reactive multilayer joining and resulting product |
| PL371683A1 (en) * | 2001-10-05 | 2005-06-27 | Intermune, Inc. | Methods of treating liver fibrosis and hepatitis c virus infection |
| EP1626836A2 (en) * | 2003-05-13 | 2006-02-22 | Reactive Nanotechnologies Inc. | Method of controlling thermal waves in reactive multilayer joining and resulting product |
| US20090098085A1 (en) * | 2006-08-11 | 2009-04-16 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| US20090035268A1 (en) * | 2007-08-01 | 2009-02-05 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
-
2000
- 2000-08-08 IL IL14761200A patent/IL147612A0/xx unknown
- 2000-08-08 KR KR1020027001782A patent/KR20020020809A/ko not_active Ceased
- 2000-08-08 HK HK03101248.5A patent/HK1048951A1/zh unknown
- 2000-08-08 HR HR20020118A patent/HRP20020118A2/hr not_active Application Discontinuation
- 2000-08-10 CO CO00059914A patent/CO5180574A1/es not_active Application Discontinuation
- 2000-08-11 AR ARP000104149A patent/AR025549A1/es not_active Application Discontinuation
-
2001
- 2001-06-20 US US09/885,773 patent/US20010046957A1/en not_active Abandoned
-
2002
- 2002-02-12 NO NO20020704A patent/NO20020704D0/no not_active Application Discontinuation
- 2002-02-13 MA MA26519A patent/MA26814A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL147612A0 (en) | 2002-08-14 |
| KR20020020809A (ko) | 2002-03-15 |
| CO5180574A1 (es) | 2002-07-30 |
| MA26814A1 (fr) | 2004-12-20 |
| NO20020704L (no) | 2002-02-12 |
| HK1048951A1 (zh) | 2003-04-25 |
| NO20020704D0 (no) | 2002-02-12 |
| US20010046957A1 (en) | 2001-11-29 |
| HRP20020118A2 (en) | 2003-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9306841A (pt) | Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico | |
| ATE515265T1 (de) | Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen | |
| RU98111594A (ru) | Фармацевтические композиции, включающие флурбипрофен | |
| BR9916860A (pt) | Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma | |
| GB2285219A (en) | Use of norastemizole for the treatment of allergic disorders | |
| WO2001012214A3 (en) | MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) | |
| KR950007848A (ko) | (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법 | |
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| AR012731A1 (es) | Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible. | |
| JP2002544227A5 (es) | ||
| AR025549A1 (es) | Mofetil micofelonato en asociacion con peg-ifn-alfa | |
| GB9023701D0 (en) | Medical treatment | |
| RU2006101061A (ru) | Азенапин для лечения шизофрении у пациентов с избыточной массой тела или предрасположенностью к избыточной массе тела | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| YU9302A (sh) | Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa | |
| ECSP003616A (es) | Micofenolato mofetil en asociacion con peg-ifn-alfa | |
| UY26292A1 (es) | Micofenolato mofetilo en asociacion con peg-ifn-a ley 17164 | |
| BR0114339A (pt) | Composições farmaceuticamente aceitáveis contendo epinastina e pseudoefedrina | |
| CO5150206A1 (es) | Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias | |
| CO5160246A1 (es) | Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias | |
| FR2647014B1 (fr) | Composition medicamenteuse pour le traitement et la prevention des symptomes de l'insuffisance cardiaque, renfermant un agent alpha-stimulant vasoconstricteur comme principe actif | |
| TH54147A (th) | ไมโคฟีโนเลท โมฟีทิล โนการเข้าร่วมกับ peg-ifn-อัลฟา | |
| KR960706352A (ko) | 대상부전성 간 질환을 가진 환자의 치료방법 및 조성물(method and composition for treatment of patients having decompensated liver disease) | |
| RU95101640A (ru) | Лекарственное средство для лечения дислипопротеидемии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |